Compare ATOM & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | PSTV |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.6M | 80.4M |
| IPO Year | 2016 | N/A |
| Metric | ATOM | PSTV |
|---|---|---|
| Price | $2.27 | $0.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 648.0K | ★ 19.8M |
| Earning Date | 02-12-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,000.00 | ★ $5,258,000.00 |
| Revenue This Year | N/A | $1.73 |
| Revenue Next Year | $300.00 | $12.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.89 | $0.16 |
| 52 Week High | $10.68 | $2.31 |
| Indicator | ATOM | PSTV |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 25.33 |
| Support Level | $2.59 | $0.21 |
| Resistance Level | $2.98 | $0.26 |
| Average True Range (ATR) | 0.32 | 0.03 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 0.79 | 16.82 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used transistor types in the semiconductor industry. The mears silicon technology of the company can be used for applications like Analog, DRAM, logic and processors, and SRAM.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).